2m 2m 2m 2m 2m 2m 2m
CEN Biotech (CENBF)
OTC
$0.0001$0.00 (0.00%)
Price as of May 27, 2026- $6,525.00Market Cap
- 9,900.00%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
CEN Biotech (CENBF)
$0.0001$0.00 (0.00%)
Annual
Quarterly
12/31/2021 | 12/31/2020 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | 626,867 N/A | N/A N/A | |
Cost of Revenue | N/A N/A | N/A N/A | |
Gross Profit | 626,867 N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | |
Research and Development Expense | 0 N/A | N/A N/A | |
Depreciation and Amortization Expense | 439,543 +3.47% | 424,812 N/A | |
Total Operating Expenses | 19.7M +673.05% | 2.5M N/A | |
Operating Profit | -19.0M +648.41% | -2.5M N/A | |
Interest Income | 504 -92.12% | 6,400 N/A | |
Interest Expense | -428,249 -86.76% | -3.2M N/A | |
Interest Income and Expense and Net | -427,745 -86.74% | -3.2M N/A | |
Total Nonoperating Income and Expense | 97,529 -99.42% | 16.8M N/A | |
Income before Taxes | -18.9M +644.58% | -2.5M N/A | |
Income Taxes | -36,356 N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | |
Net Income | -18.9M -232.66% | 14.2M N/A | |
Net Income from Continuing Operations Applicable to Common | -18.9M -232.92% | 14.2M N/A | |
Basic EPS and Net Income | -0.45 -186.54% | 0.52 N/A | |
Diluted EPS and Net Income | -0.45 -200.00% | 0.45 N/A | |
Basic Weighted Average Shares | 42.4M +55.58% | 27.3M N/A | |
Diluted Weighted Average Shares | 42.4M +29.59% | 32.7M N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 193,198 +10,025.68% | 1,908 N/A | |
Short-Term Investments | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 193,198 +10,025.68% | 1,908 N/A | |
Total Current Assets | 472,221 +2,283.87% | 19,809 N/A | |
Accumulated Depreciation | 22,041 N/A | N/A N/A | |
Property and Plant and Equipment and Net | 97,403 N/A | N/A N/A | |
Total Long-Term Assets | 97,403 N/A | N/A N/A | |
Total Assets | 8.4M +33.68% | 6.3M N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | |
Total Short-Term Debt | 5.0M -41.08% | 8.5M N/A | |
Total Current Liabilities | 9.9M -32.95% | 14.7M N/A | |
Total Long-Term Debt | 31,552 -59.55% | 78,000 N/A | |
Total Long-Term Liabilities | 206,763 +45.50% | 142,102 N/A | |
Total Liabilities | 10.1M -38.07% | 16.3M N/A | |
Retained Earnings | -46.0M +69.86% | -27.1M N/A | |
Total Stockholders Equity | -1.7M -83.40% | -10.0M N/A | |
Total Shares Outstanding | 56.0M +103.06% | 27.6M N/A | |
Cash Flow | |||
Cash from Operating Activities | -335,504 -1.54% | -340,749 N/A | |
Capital Expenditures | 23,213 N/A | N/A N/A | |
Cash from Investing Activities | 9,937 +107.64% | -130,100 N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | 520,830 +11.05% | 469,000 N/A | |
Financials Ratio | |||
Gross Margin | N/A N/A | N/A N/A | |
Operating Margin | -3,036.93% N/A | N/A N/A | |
Return on Assets | -256.23% -222.37% | 209.39% N/A | |
Return on Equity | 324.53% +504.56% | -80.22% N/A | |
Revenue Growth | N/A N/A | N/A N/A | |
Current Ratio | 0.05 +3,584.62% | 0.001 N/A | |
Cash Ratio | 0.02 +19,500.00% | 0.0001 N/A | |
Debt-to-Equity Ratio | -3.05 +254.06% | -0.86 N/A | |
Debt-to-Assets Ratio | 0.60 -56.05% | 1.37 N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow